Health Canada Issues Counterfeit GLP-1 Drug Warning

Warning Covers Popular Brand Names

The regulatory agency's advisory specifically mentions concerns about counterfeit versions of Ozempic, Wegovy, Rybelsus, and Mounjaro, as well as Zepbound. The warning comes as demand for these medications continues to outpace supply across Canadian pharmacies.

Health Canada emphasizes that consumers should only obtain these medications through legitimate healthcare providers and licensed Canadian pharmacies. The agency has not disclosed specific details about the number or locations of counterfeit products discovered.

Timing Coincides with Supply Pressures

The counterfeit warning arrives as Canada experiences ongoing supply constraints for brand-name GLP-1 medications. Health Canada is currently reviewing nine applications for generic semaglutide products, with decisions expected later in 2026 following the agency's 180-day review timeline.

The regulatory review includes submissions from established generic manufacturers including Sandoz Canada, Apotex, Teva Canada, and others. Canadian company Vimy Pharma has indicated plans to submit its domestic manufacturing application in the coming weeks.

Consumer Safety Recommendations

Health Canada's advisory provides specific guidance for consumers considering GLP-1 medications:

• Only purchase medications from licensed Canadian pharmacies
• Verify prescriptions are issued by qualified healthcare providers
• Be cautious of online sellers offering discounted or "generic" versions not yet approved in Canada
• Report suspected counterfeit products to Health Canada's MedEffect reporting system

The agency notes that unauthorized products may contain incorrect dosages, contaminated ingredients, or no active pharmaceutical ingredients at all.

Market Context and Pricing Pressures

Current Canadian retail prices for brand-name semaglutide products range from approximately $300-400 per month at major pharmacy chains including Shoppers Drug Mart, Costco Pharmacy, and Walmart Pharmacy. These high costs, combined with limited insurance coverage, may drive some consumers toward unauthorized sources.

Industry analysts expect legitimate generic competition to begin reaching Canadian pharmacies in the second half of 2026, potentially reducing costs by 30-50% compared to current brand pricing. Until then, patients seeking these medications should work with their healthcare providers and use our generic semaglutide tracker for updates on approved alternatives.

Regulatory Enforcement Actions

Health Canada has not announced specific enforcement actions related to the counterfeit warning, but the agency maintains authority to issue stop-sale orders, conduct facility inspections, and coordinate with law enforcement agencies for serious violations.

The regulatory body continues to process applications for legitimate generic alternatives while monitoring the Canadian pharmaceutical supply chain for unauthorized products. Consumers with questions about medication authenticity can consult our FAQ section or contact Health Canada directly.